Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Journal of the American Academy of Dermatology|September 8, 2022
Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysisXiaoting Wei, Yu Chen, Hong Yao, et al.
Nature Communications|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanomaLili Mao, Yumei Lai, Hong Zheng, et al.
Annals of Surgical Oncology|April 8, 2020
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral MelanomaXiaoting Wei, Di Wu, Hang Li, et al.
The British Journal of Dermatology|March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational studyXue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
Pageof 13